Platelet Reactivity After Receiving Clopidogrel Among Moderate CKD Patients Undergoing PCI

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-04-30

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dual antiplatelet therapy (DAPT) with standard doses of aspirin and clopidogrel has long been the cornerstone in patients undergoing percutaneous coronary intervention (PCI). However, inhibition of platelet activation and aggregation after DAPT varies greatly among patients. Some clinical studies have demonstrated that patients with high on-treatment platelet reactivity are at increased risk of major adverse cardiovascular events. Tailored antiplatelet therapy seems offer an opportunity to improve outcomes after coronary stenting by drug adjustment based on platelet function testing. Unfortunately, the results of 3 major prospective trials (GRAVITAS, ARCTIC, TRIGGER PCI) of personalized antiplatelet therapy are neutral. In these studies, platelet function was only assessed by a single measurement and a single method early after the start of antiplatelet treatment. To test the stability of platelet reactivity measurements over time among patients undergoing PCI, investigators use 3 methods (VerifyNow P2Y12 assay, Flow cytometric assessment of the phosphorylation status of VASP, light transmittance aggregometry) for platelet function testing in 2 periods (\~14days), with maintenance doses of clopidogrel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Amlodipine on Anti-platelet Drug Effect in Patients With Coronary Artery Disease

NCT01203696

Ischemic Heart Disease

COMPLETED PHASE4

Impact of Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring in Patients With High on Treatment Platelet Reactivity Undergoing Percutaneous Coronary Intervention

NCT01505790

Acute Coronary Syndromes

COMPLETED PHASE3

Platelet Reactivity in PAD Undergoing Percutaneous Angioplasty

NCT04165629

Peripheral Artery Disease Critical Limb Ischemia Claudication, Intermittent

UNKNOWN

Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype

NCT01710436

Coronary Heart Disease

UNKNOWN

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

NCT01582217

Percutaneous Coronary Intervention Dual Antiplatelet Therapy Aspirin +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moderate CKD Patients Undergoing PCI

No interventions assigned to this group

Normal renal function Patients Undergoing PCI

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. \>18 years old.

2.15 ≤ eGFR \< 60 ml/min/1.73 m2.

3\. Clinically stable and following PCI between 4 weeks and 1 year.

4\. On clopidogrel (75mg/d) and aspirin (100mg/d) treatment at least 4 weeks.